- Home
- CYBN vs OBIO Comparison
CYBN vs OBIO Comparison
Compare CYBN & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- OBIO
- Stock Information
- Founded
- CYBN 2019
- OBIO 2017
- Country
- CYBN Canada
- OBIO United States
- Employees
- CYBN N/A
- OBIO N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CYBN Health Care
- OBIO Health Care
- Exchange
- CYBN Nasdaq
- OBIO Nasdaq
- Market Cap
- CYBN 127.3M
- OBIO 151.3M
- IPO Year
- CYBN N/A
- OBIO N/A
- Fundamental
- Price
- CYBN $7.96
- OBIO $2.85
- Analyst Decision
- CYBN Strong Buy
- OBIO Strong Buy
- Analyst Count
- CYBN 4
- OBIO 5
- Target Price
- CYBN $86.00
- OBIO $14.20
- AVG Volume (30 Days)
- CYBN 326.6K
- OBIO 193.1K
- Earning Date
- CYBN 06-25-2025
- OBIO 05-12-2025
- Dividend Yield
- CYBN N/A
- OBIO N/A
- EPS Growth
- CYBN N/A
- OBIO N/A
- EPS
- CYBN N/A
- OBIO N/A
- Revenue
- CYBN N/A
- OBIO $2,886,000.00
- Revenue This Year
- CYBN N/A
- OBIO $21.38
- Revenue Next Year
- CYBN N/A
- OBIO $31.89
- P/E Ratio
- CYBN N/A
- OBIO N/A
- Revenue Growth
- CYBN N/A
- OBIO 30.23
- 52 Week Low
- CYBN $4.81
- OBIO $2.37
- 52 Week High
- CYBN $13.88
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- CYBN 61.23
- OBIO 49.08
- Support Level
- CYBN $7.00
- OBIO $2.61
- Resistance Level
- CYBN $8.50
- OBIO $3.02
- Average True Range (ATR)
- CYBN 0.53
- OBIO 0.18
- MACD
- CYBN 0.15
- OBIO 0.04
- Stochastic Oscillator
- CYBN 76.00
- OBIO 60.19
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.